Secukinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients aged six years and older.
Piotr K KrajewskiJacek Cezary SzepietowskiPublished in: Expert review of clinical immunology (2023)
Although there are only two clinical trials assessing the efficacy and safety of secukinumab in the pediatric population with plaque PSO, this therapy seems to be a significant advancement in managing those patients. Both dose regimens (depending on the weight, low-dose, 75/75/150 mg, and high-dose 75/150/300 mg) of secukinumab were more effective in achieving significant clinical improvement (PASI 75/90 and IGA response) than placebo or active-comparator. Both regimens showed good safety and tolerability profiles, with mostly mild AEs and no SAEs observed.
Keyphrases
- low dose
- high dose
- end stage renal disease
- clinical trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- emergency department
- intensive care unit
- prognostic factors
- physical activity
- early onset
- randomized controlled trial
- patient reported outcomes
- high intensity
- body mass index
- smoking cessation
- cell therapy